1282P Trial-based costs of all-cause adverse events in first-line therapy for advanced non-small cell lung cancer: Findings from CheckMate-227
| Autor: | Lubinga, S.J., King, S.B., Betts, K.A., Rao, S., Castriota, F., Mahin, M., Orvis, E., Marathe, S., Ma, J., Stenehjem, D. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S827-S828 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|